Medical Cost Of Care By Line Of Treatment (Lot) In Medicare Fee-For-Service (Ffs) Beneficiaries With Kras-Mutated Metastatic Non-Small Cell Lung Cancer (Mnsclc).

Tara Matsuda,Aurelien Jamotte,Ann Xi,Barton Jones,Allison Petrilla,Nathan Markward,Anne Murunga,Kendall Lee Stevinson

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览3

暂无评分

摘要

63Background: While no targeted therapy is currently approved for patients with KRAS-mutated mNSCLC, new therapies are being developed for patients with KRAS p.G12C-mutated NSCLC. However, real-wor...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要